Johnson & Johnson Company Profile (NYSE:JNJ)

About Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson logoJohnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:JNJ
  • CUSIP: 47816010
  • Web:
  • Market Cap: $381.23534 billion
  • Outstanding Shares: 2,683,999,000
Average Prices:
  • 50 Day Moving Avg: $133.77
  • 200 Day Moving Avg: $130.75
  • 52 Week Range: $109.32 - $143.62
  • Trailing P/E Ratio: 24.77
  • Foreward P/E Ratio: 18.16
  • P/E Growth: 2.80
Sales & Book Value:
  • Annual Revenue: $74.36 billion
  • Price / Sales: 5.14
  • Book Value: $26.78 per share
  • Price / Book: 5.32
  • Annual Dividend: $3.36
  • Dividend Yield: 2.4%
  • EBITDA: $25.02 billion
  • Net Margins: 21.28%
  • Return on Equity: 27.68%
  • Return on Assets: 13.41%
  • Debt-to-Equity Ratio: 0.38%
  • Current Ratio: 1.34%
  • Quick Ratio: 1.01%
  • Average Volume: 5.36 million shs.
  • Beta: 0.78
  • Short Ratio: 2.41

Frequently Asked Questions for Johnson & Johnson (NYSE:JNJ)

What is Johnson & Johnson's stock symbol?

Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."

How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?

Johnson & Johnson declared a quarterly dividend on Thursday, October 19th. Shareholders of record on Tuesday, November 28th will be given a dividend of $0.84 per share on Tuesday, December 12th. This represents a $3.36 annualized dividend and a yield of 2.36%. The ex-dividend date is Monday, November 27th. View Johnson & Johnson's Dividend History.

How were Johnson & Johnson's earnings last quarter?

Johnson & Johnson (NYSE:JNJ) issued its quarterly earnings results on Tuesday, October, 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.80 by $0.10. The company had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.68%. The firm's revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.68 earnings per share. View Johnson & Johnson's Earnings History.

When will Johnson & Johnson make its next earnings announcement?

Johnson & Johnson is scheduled to release their next quarterly earnings announcement on Tuesday, January, 23rd 2018. View Earnings Estimates for Johnson & Johnson.

What guidance has Johnson & Johnson issued on next quarter's earnings?

Johnson & Johnson issued an update on its FY17 earnings guidance on Tuesday, October, 17th. The company provided earnings per share guidance of $7.25-7.30 for the period, compared to the Thomson Reuters consensus estimate of $7.18. The company issued revenue guidance of $76.1-76.5 billion, compared to the consensus revenue estimate of $75.84 billion.

Where is Johnson & Johnson's stock going? Where will Johnson & Johnson's stock price be in 2017?

20 brokers have issued 12-month price targets for Johnson & Johnson's shares. Their forecasts range from $110.00 to $165.00. On average, they anticipate Johnson & Johnson's share price to reach $141.63 in the next year. View Analyst Ratings for Johnson & Johnson.

What are analysts saying about Johnson & Johnson stock?

Here are some recent quotes from research analysts about Johnson & Johnson stock:

  • 1. According to Zacks Investment Research, "Sales in J&J’s domestic Pharma segment have decelerated this year as a number of key growth drivers like Remicade and Concerta are facing competition.  However, J&J is optimistic that sales growth will accelerate in 2H. We believe that new drugs like Xarelto, Stelara, Darzalex, and Imbruvica remain the key to growth. Meanwhile, share buybacks and restructuring initiatives should provide bottom-line support. J&J is also making rapid progress with its pipeline and line extensions. However, J&J’s shares have underperformed the industry this year so far. Headwinds like negative currency movement, generics, pricing pressure and soft global market conditions remain. Sluggish growth in the Consumer segment is also a concern. Meanwhile, HCV sales continue to decline amid intense competition.  Estimates have remained mostly stable ahead of the Q3 results. J&J has a positive record of earnings surprises in recent quarters." (10/4/2017)
  • 2. BTIG Research analysts commented, "Yesterday, we attended JNJ’s Pharma day held in New Brunswick, NJ. The overarching theme of the day was the expectation that the Pharma business outgrows the IMS projected ~5% 5-year CAGR for branded drugs. Our model is significantly below such expectations, as we have reported growth of ~6.5% during 2017 falling to ~3.6% in 2018 and essentially flat through 2020. Our numbers may prove conservative given that we do not currently include new drug launches of esketamine, guselkumab and sirukumab. We remain Neutral, as we think that the Oncology landscape is becoming more complicated and the Immunology portfolio may underperform internal expectations as a new class of oral drugs comes to market." (5/21/2017)
  • 3. UBS AG analysts commented, "After making appropriate adjustments for year-over-year shipping day differences, JNJ's Q4 sales were up an impressive 9.5% in the U.S., and up 7.6% CC WW. Initial 2017 outlook calls for sales of $74.1-74.8 bil (up 4-5% CC) and EPS of $6.93-7.08 (including the AMO deal). As previewed, the guided range reflects greater impact from FX, and by our estimation a degree of conservatism. Given the continued strong growth of key Pharma franchises, management's potential to drive stable to improving margins, the ~$2.5 bil remaining repurchase authorization and other factors, we see flex and potential upside to management's initial 2017 outlook. We reiterate our Buy rating on top large-cap diversified pick JNJ, trimming our target from $142 to $141 due primarily to the ~$4.3 bil cash outlay for AMO, expected to close in 1Q17." (1/25/2017)
  • 4. Jefferies Group LLC analysts commented, "With biosimilars and generics expected to drag the next few years, we expect JNJ will continue look to M&A to augment growth. Whilst this should ultimately drive better growth, we believe that investors will not reward the shares for this initially." (1/5/2017)

Who are some of Johnson & Johnson's key competitors?

Who are Johnson & Johnson's key executives?

Johnson & Johnson's management team includes the folowing people:

  • Alex Gorsky, Chairman of the Board, Chief Executive Officer
  • Dominic J. Caruso, Chief Financial Officer, Executive Vice President
  • Peter M. Fasolo Ph.D., Chief Human Resource Officer, Executive Vice President
  • Paulus A. Stoffels, Executive Vice President, Chief Scientific Officer
  • Michael H. Ullmann, Executive Vice President, General Counsel
  • Joaquin Duato, Executive Vice President, Worldwide Chairman - Pharmaceuticals
  • Jorge S. Mesquita, Executive Vice President, Worldwide Chairman - Consumer
  • Sandra E. Peterson, Executive Vice President - Group Worldwide Chairman
  • Joseph Wolk, Vice President - Investor Relations
  • Anne M. Mulcahy, Lead Independent Director

Who owns Johnson & Johnson stock?

Johnson & Johnson's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (0.44%), APG Asset Management N.V. (0.26%), Sanders Capital LLC (0.19%), PGGM Investments (0.11%), Assenagon Asset Management S.A. (0.06%) and Robeco Institutional Asset Management B.V. (0.04%). Company insiders that own Johnson & Johnson stock include Charles Prince, Dominic J Caruso, Gary J Pruden, Paulus Stoffels, Peter Fasolo and Ronald A Kapusta. View Institutional Ownership Trends for Johnson & Johnson.

Who sold Johnson & Johnson stock? Who is selling Johnson & Johnson stock?

Johnson & Johnson's stock was sold by a variety of institutional investors in the last quarter, including Private Asset Management Inc., Tukman Grossman Capital Management Inc., State Treasurer State of Michigan, Sabal Trust CO, Robeco Institutional Asset Management B.V., Bridges Investment Counsel Inc., Focused Investors LLC and Meeder Asset Management Inc.. Company insiders that have sold Johnson & Johnson stock in the last year include Dominic J Caruso and Paulus Stoffels. View Insider Buying and Selling for Johnson & Johnson.

Who bought Johnson & Johnson stock? Who is buying Johnson & Johnson stock?

Johnson & Johnson's stock was purchased by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Assenagon Asset Management S.A., Sanders Capital LLC, Fisher Asset Management LLC, Shell Asset Management Co., PGGM Investments, Rockefeller Financial Services Inc. and Montrusco Bolton Investments Inc.. View Insider Buying and Selling for Johnson & Johnson.

How do I buy Johnson & Johnson stock?

Shares of Johnson & Johnson can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Johnson & Johnson's stock price today?

One share of Johnson & Johnson stock can currently be purchased for approximately $142.40.

MarketBeat Community Rating for Johnson & Johnson (NYSE JNJ)
Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  487 (Vote Outperform)
Underperform Votes:  582 (Vote Underperform)
Total Votes:  1,069
MarketBeat's community ratings are surveys of what our community members think about Johnson & Johnson and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Johnson & Johnson (NYSE:JNJ) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Sell Ratings, 7 Hold Ratings, 9 Buy Ratings
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $141.63 (0.54% downside)
Consensus Price Target History for Johnson & Johnson (NYSE:JNJ)
Price Target History for Johnson & Johnson (NYSE:JNJ)
Analysts' Ratings History for Johnson & Johnson (NYSE:JNJ)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/19/2017Credit Suisse GroupSet Price TargetOutperform$147.00 -> $154.00N/AView Rating Details
10/16/2017Jefferies Group LLCBoost Price TargetBuy$157.00 -> $160.00N/AView Rating Details
10/18/2017Barclays PLCBoost Price TargetEqual Weight$140.00 -> $148.00N/AView Rating Details
10/18/2017Cowen and CompanyReiterated RatingOutperform$147.00 -> $155.00N/AView Rating Details
10/18/2017Morgan StanleyReiterated RatingHold$140.00 -> $145.00N/AView Rating Details
10/18/2017ArgusBoost Price TargetBuy -> Positive$145.00 -> $165.00N/AView Rating Details
10/18/2017Wells Fargo & CompanyReiterated RatingOutperform$149.00 -> $155.00N/AView Rating Details
10/18/2017BMO Capital MarketsReiterated RatingOutperform -> Positive$145.00 -> $152.00N/AView Rating Details
10/18/2017Stifel NicolausBoost Price TargetHold -> Hold$140.00 -> $142.00N/AView Rating Details
10/18/2017Royal Bank Of CanadaBoost Price TargetOutperform -> Outperform$144.00 -> $147.00N/AView Rating Details
10/18/2017Leerink SwannReiterated RatingOutperform -> Outperform$150.00 -> $165.00N/AView Rating Details
10/4/2017Piper Jaffray CompaniesReiterated RatingHold$120.00LowView Rating Details
9/25/2017Citigroup Inc.Initiated CoverageNeutral -> Neutral$140.00LowView Rating Details
9/20/2017Goldman Sachs Group IncDowngradeNeutral -> Sell$125.00 -> $130.00LowView Rating Details
8/16/2017J P Morgan Chase & CoBoost Price TargetOverweight$140.00 -> $148.00LowView Rating Details
7/21/2017Alembic Global AdvisorsDowngradeNeutral -> UnderweightLowView Rating Details
7/21/2017Atlantic SecuritiesDowngradeNeutral -> Underweight$113.00LowView Rating Details
7/21/2017BTIG ResearchDowngradeNeutral -> Sell$110.00LowView Rating Details
11/28/2016Bank of America CorporationReiterated RatingHold$126.00N/AView Rating Details
10/23/2016Societe GeneraleReiterated RatingHold$116.00N/AView Rating Details
8/19/2016Deutsche Bank AGReiterated RatingBuy$142.00N/AView Rating Details
5/20/2016Raymond James Financial, Inc.Reiterated RatingOutperform$120.00N/AView Rating Details
5/20/2016Standpoint ResearchInitiated CoverageSell$94.00N/AView Rating Details
1/27/2016Independent Research GmbHSet Price TargetNeutral$108.00N/AView Rating Details
(Data available from 10/21/2015 forward)


Earnings History for Johnson & Johnson (NYSE:JNJ)
Earnings by Quarter for Johnson & Johnson (NYSE:JNJ)
Earnings History by Quarter for Johnson & Johnson (NYSE JNJ)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/17/2017Q3 2017$1.80$1.90$19.29 billion$19.65 billionViewN/AView Earnings Details
7/18/2017Q2 2017$1.79$1.83$18.94 billion$18.84 billionViewN/AView Earnings Details
4/18/2017Q1 17$1.77$1.83$18.02 billion$17.77 billionViewN/AView Earnings Details
1/24/2017Q416$1.56$1.58$18.28 billion$18.10 billionViewN/AView Earnings Details
10/18/2016Q316$1.65$1.68$17.71 billion$17.80 billionViewListenView Earnings Details
7/19/2016Q216$1.68$1.74$17.98 billion$18.50 billionViewListenView Earnings Details
4/19/2016Q116$1.65$1.68$17.50 billion$17.50 billionViewListenView Earnings Details
1/26/2016Q415$1.42$1.44$17.88 billion$17.80 billionViewListenView Earnings Details
10/13/2015Q315$1.45$1.49$17.47 billion$17.10 billionViewListenView Earnings Details
7/14/2015Q215$1.69$1.71$17.76 billion$17.80 billionViewListenView Earnings Details
4/14/2015Q115$1.54$1.56$17.31 billion$17.37 billionViewListenView Earnings Details
1/20/2015Q414$1.25$1.27$18.59 billion$18.30 billionViewListenView Earnings Details
10/14/2014Q314$1.42$1.50$18.41 billion$18.50 billionViewListenView Earnings Details
7/15/2014Q214$1.54$1.66$18.86 billion$19.50 billionViewN/AView Earnings Details
4/15/2014Q114$1.48$1.54$18.00 billion$18.10 billionViewN/AView Earnings Details
1/21/2014Q413$1.20$1.24$17.95 billion$18.40 billionViewN/AView Earnings Details
10/15/2013Q313$1.32$1.36$17.46 billion$17.60 billionViewN/AView Earnings Details
7/16/2013Q2 2013$1.39$1.48$17.71 billion$17.90 billionViewN/AView Earnings Details
4/16/2013Q1 2013$1.41$1.44$17.46 billion$17.50 billionViewN/AView Earnings Details
1/22/2013Q4 2012$1.17$1.19$17.67 billion$17.60 billionViewN/AView Earnings Details
10/16/2012$1.21$1.25ViewN/AView Earnings Details
7/17/2012$1.29$1.30ViewN/AView Earnings Details
4/17/2012$1.34$1.37ViewN/AView Earnings Details
1/24/2012$1.09$1.13ViewN/AView Earnings Details
10/18/2011$1.21$1.24ViewN/AView Earnings Details
7/19/2011$1.24$1.28ViewN/AView Earnings Details
4/19/2011$1.26$1.35ViewN/AView Earnings Details
1/25/2011$1.03$1.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Johnson & Johnson (NYSE:JNJ)
2017 EPS Consensus Estimate: $7.08
2018 EPS Consensus Estimate: $7.99
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$1.71$1.77$1.74
Q2 20172$1.75$1.86$1.81
Q3 20171$1.84$1.84$1.84
Q4 20171$1.69$1.69$1.69
Q1 20181$1.99$1.99$1.99
Q2 20181$2.01$2.01$2.01
Q3 20181$2.18$2.18$2.18
Q4 20181$1.81$1.81$1.81
(Data provided by Zacks Investment Research)


Current Dividend Information for Johnson & Johnson (NYSE:JNJ)
Next Dividend:12/12/2017
Annual Dividend:$3.36
Dividend Yield:2.36%
Dividend Growth:6.70% (3 Year Average)
Payout Ratio:58.33% (Trailing 12 Months of Earnings)
46.15% (Based on This Year's Estimates)
42.86% (Based on Next Year's Estimates)
Track Record:54 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Johnson & Johnson (NYSE:JNJ)

Dividend History by Quarter for Johnson & Johnson (NYSE JNJ)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Johnson & Johnson (NYSE:JNJ)
Insider Ownership Percentage: 0.19%
Institutional Ownership Percentage: 65.90%
Insider Trades by Quarter for Johnson & Johnson (NYSE:JNJ)
Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)
Insider Trades by Quarter for Johnson & Johnson (NYSE:JNJ)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/24/2017Paulus StoffelsVPSell102,692$133.14$13,672,412.88View SEC Filing  
7/20/2017Dominic J CarusoVPSell82,591$136.72$11,291,841.52View SEC Filing  
2/15/2017Paulus StoffelsVPSell22,000$117.29$2,580,380.00View SEC Filing  
10/21/2016Charles PrinceDirectorBuy875$114.11$99,846.25View SEC Filing  
7/26/2016Dominic J CarusoVPSell41,146$125.01$5,143,661.46View SEC Filing  
7/22/2016Ronald A KapustaCAOSell2,935$125.01$366,904.35View SEC Filing  
6/7/2016Gary J PrudenVPSell9,735$116.03$1,129,552.05View SEC Filing  
6/7/2016Ronald A KapustaCAOSell3,000$115.79$347,370.00View SEC Filing  
5/10/2016Ronald A KapustaCAOSell3,957$114.77$454,144.89View SEC Filing  
2/17/2016Paulus StoffelsinsiderSell125,000$102.43$12,803,750.00View SEC Filing  
2/3/2016Peter FasoloVPSell151,385$104.12$15,762,206.20View SEC Filing  
10/23/2015Ronald A. KapustaCAOSell6,239$99.68$621,903.52View SEC Filing  
6/2/2015Charles PrinceDirectorBuy2,500$99.22$248,050.00View SEC Filing  
4/28/2015Paulus StoffelsInsiderSell187,250$100.73$18,861,692.50View SEC Filing  
9/10/2014James CullenDirectorSell2,446$104.12$254,677.52View SEC Filing  
5/5/2014Stephen CosgroveInsiderSell22,000$100.05$2,201,100.00View SEC Filing  
3/14/2014Peter FasoloVPSell6,824$93.15$635,655.60View SEC Filing  
8/14/2013Stephen CosgroveInsiderSell17,200$91.39$1,571,908.00View SEC Filing  
8/5/2013Michael UllmannVPSell16,140$93.68$1,511,995.20View SEC Filing  
7/25/2013Paulus StoffelsInsiderSell45,440$92.40$4,198,656.00View SEC Filing  
7/18/2013Dominic J CarusoCFOSell30,000$90.31$2,709,300.00View SEC Filing  
11/12/2012James CullenDirectorSell13,900$69.70$968,830.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Johnson & Johnson (NYSE:JNJ)
Latest Headlines for Johnson & Johnson (NYSE:JNJ)
DateHeadline logoReversed: Johnson & Johnson $72 million cancer verdict - October 21 at 7:05 PM logo$417M award in lawsuit linking Johnson & Johnson baby powder to cancer gets tossed - October 21 at 7:05 PM logoWeekly Wrap: Stocks Hit New Highs as Earnings Roll In - October 21 at 7:05 PM logo Analysts Expect Johnson & Johnson (JNJ) Will Post Quarterly Sales of $20.21 Billion - October 21 at 8:15 AM logoCalifornia judge tosses $417M talc cancer verdict against J&J - October 21 at 7:19 AM logoJohnson & Johnson Does It Again - October 21 at 3:35 AM logoJudge Tosses $417M Award Against Johnson & Johnson in Cancer Case - October 21 at 3:35 AM logoHealthcare ETF (VHT) Hits New 52-Week High - October 21 at 3:34 AM logoJ&J Wins Reversal of $417 Million California Talc Verdict - October 21 at 3:34 AM logoCalifornia judge tosses $417 million talc cancer verdict against J&J - October 21 at 3:34 AM logoJudge tosses $417M award against Johnson & Johnson - October 21 at 3:34 AM logoJudge tosses $417-million award against Johnson & Johnson - October 21 at 12:43 AM logoEquities Analysts Issue Forecasts for Johnson & Johnson's FY2019 Earnings (JNJ) - October 20 at 6:52 PM logoFY2018 EPS Estimates for Johnson & Johnson (JNJ) Lowered by Jefferies Group - October 20 at 5:26 PM logoJohnson & Johnson’s (JNJ) Strong Quant Score Makes it a Buy - October 20 at 7:31 AM logoJohnson & Johnson: Fully Priced As Operating Momentum ... - Seeking Alpha - October 20 at 1:43 AM logoJohnson & Johnson to acquire Surgical Process Institute - Seeking Alpha - October 20 at 1:43 AM logoIs It Time To Take Profits On Johnson & Johnson? - Seeking Alpha - October 20 at 1:43 AM logoJohnson & Johnson (JNJ) Given a $154.00 Price Target by Credit Suisse Group Analysts - October 19 at 1:44 PM logoFY2017 EPS Estimates for Johnson & Johnson Increased by Analyst (JNJ) - October 19 at 9:40 AM logoFY2017 EPS Estimates for Johnson & Johnson (JNJ) Boosted by Jefferies Group - October 19 at 9:40 AM logoJohnson & Johnson (JNJ) Expected to Post Earnings of $1.72 Per Share - October 19 at 9:06 AM logoJohnson & Johnson (JNJ) Plans Quarterly Dividend of $0.84 - October 19 at 8:36 AM logoJohnson & Johnson to acquire Surgical Process Institute - October 19 at 7:41 AM logoJ&J: Unattractive - Seeking Alpha - October 19 at 1:34 AM logoCramer Remix: Johnson & Johnson is out of battleground territory - CNBC - October 18 at 8:32 PM logoJohnson & Johnson earnings: All eyes on hurricane impact - MarketWatch - October 18 at 3:30 PM logoJohnson & Johnson Wins Reversal of $72 Million Verdict Over Talc Cancer Risks - Fortune - October 18 at 3:30 PM logoJohnson & Johnson (JNJ) PT Raised to $161 at Jefferies - - October 18 at 3:30 PM logoUnderstanding Johnson & Johnson's Spectacular Q3 Performance - Seeking Alpha - October 18 at 3:30 PM logoJohnson & Johnson (JNJ) Q3 2017 Results - Earnings Call Transcript - Seeking Alpha - October 18 at 3:30 PM logoJohnson & Johnson: One-Time Bumps - Seeking Alpha - October 18 at 3:30 PM logoStock Market News For Oct 18, 2017 - October 18 at 3:30 PM logoJohnson & Johnson (JNJ) Given "Hold" Rating at Barclays PLC - October 18 at 1:24 PM logoRoyal Bank Of Canada Raises Johnson & Johnson (JNJ) Price Target to $147.00 - October 18 at 8:26 AM logoJohnson & Johnson (JNJ) Price Target Raised to $142.00 - October 18 at 8:26 AM logoJohnson & Johnson: Amazing Company, But There Is Something Wrong - October 18 at 5:36 AM logoJohnson & Johnson Outlook Buoyed by Drug Unit - October 18 at 5:36 AM
News IconJohnson & Johnson wins the reversal of a $72 million verdict over a cancer death linked to one of its popular products - October 18 at 5:36 AM logoCramer pushes back against 'peak earnings' theory with 5 ... - October 18 at 5:36 AM logoCramer Remix: The big problem that triggered Netflix’s decline - October 18 at 5:35 AM logoCramer: Stocks May Be Cheaper Than We Think - October 18 at 5:35 AM logoCramer Remix: The big problem that triggered Netflix’s de... - October 18 at 5:35 AM logo3 Things You Won't Learn by Focusing on Johnson & Johnson's Headline Figures in Its Q3 Report - October 18 at 5:35 AM logoA big employer is finally addressing a major pain point for job applicants - October 18 at 5:35 AM logo[$$] Johnson & Johnson Outlook Buoyed by Drug Unit - October 18 at 5:35 AM logoEdited Transcript of JNJ earnings conference call or presentation 17-Oct-17 12:30pm GMT - October 18 at 5:35 AM logo3 Things You Won't Learn by Focusing on Johnson & Johnson's Headline Figures in Its Q3 Report - October 17 at 10:19 PM logoJohnson & Johnson gets court reversal of verdict over talc cancer risks - October 17 at 6:41 PM logoJohnson & Johnson Q3 2017 Earnings Conference Call Transcript (JNJ) - October 17 at 4:17 PM



Johnson & Johnson (JNJ) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.